Avotres

Avotres Inc. is a privately held biotechnology company developing breakthrough therapeutic solutions for incurable immune-mediated diseases. Addressing these areas of unmet medical need, Avotres applies innovative science to uncover paradigm-shifting immunological pathways with the hope of transforming treatment for millions of patients. Avotres' mission is to fundamentally address these diseases and aims to achieve the goal of reducing the disease burden for patients.Avotres’ lead asset, AVT001, is a cell therapy designed to address the common root cause of autoimmune diseases: the loss of self-tolerance. By targeting the novel Qa-1/HLA-E-restricted CD8+ regulatory T cell (Q/E CD8+ Treg)-mediated pathway, AVT001 has the potential to restore self-tolerance in patients with autoimmune diseases, thereby creating a robust platform to effectively treat a wide range of autoimmune diseases as a disease modifier.